Pharmaceutical News

RSS

Viral Genetics cautions investors and the public to rely only on its own releases and disclosures

Viral Genetics (Pink Sheets: VRAL), a biotechnology company that develops drug compounds for HIV/AIDS, autoimmune diseases, and cancer, is issuing this announcement in response to a series of press releases distributed by collegestock.com on August 25 and August 26, and an article published on Today's Financial News entitled "TFN Reader Grapevine: There's Something About Viral Genetics, Inc. (VRAL)," on August 25.

27 Aug 2009

European Medicines Agency validates Schering-Plough's MAA for nomegestrol acetate/17 beta-estradiol

Schering-Plough Corporation, (NYSE: SGP), today announced that the European Medicines Agency (EMEA) has validated (accepted for review) the company's Marketing Authorization Application (MAA) for a fixed-dose combination of mometasone furoate and formoterol fumarate for the maintenance treatment of asthma in patients 12 years of age and older.

27 Aug 2009

Prescription Solutions launches consumer website that features updated content and drug pricing tool

Prescription Solutions, a leading pharmacy benefits management organization and a UnitedHealth Group (NYSE: UNH) company, today announced the launch of its refreshed consumer website, www.PrescriptionSolutions.com, featuring enhanced functionality, updated content, and simplified navigation. The site makes prescription drug information more accessible and provides education customers need to make informed health care choices.

27 Aug 2009

XenaCare Holdings to market Cobroxin pain reliever drug in U.S.

Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it has successfully completed a licensing agreement that grants XenaCare Holdings (OTCBB:XCHO) ongoing exclusive United States marketing and distribution rights for Cobroxin in return for meeting specific minimum performance requirements.

27 Aug 2009

European Medicines Agency accepts reviewal of Merck's MAA for regulatory approval of vernakalant IV

Merck & Co., Inc., Whitehouse Station, NJ, USA, which operates in many countries as Merck Sharp & Dohme Limited, announced today that the European Medicines Agency (EMEA) accepted for review the Company’s Marketing Authorisation Application (MAA) for regulatory approval of vernakalant intravenous (IV).

27 Aug 2009

Rizer XL's male enhancement formula increases sexual desire, pleasure and performance

Increasing pressure on men to perform sexually and higher expectations of men's sexual performance from women has led to an astounding rise in sales, says Rizer XL, the leading provider of premium male enhancement pills.

27 Aug 2009

QRxPharma completes its pilot evaluation study investigating the efficacy of MoxDuo capsules

QRxPharma Limited and announced today successful completion of its pilot study to evaluate the analgesic efficacy and safety profile of MoxDuo(TM) IR (immediate release) capsules in patients with moderate to severe pain following total knee replacement surgery.

27 Aug 2009

Walgreens collaborates with Caterpillar to provide transparent prescription drug pricing for employers

Walgreens today announced an agreement with Caterpillar Inc. (NYSE: CAT) that establishes a direct relationship for the purchase of prescription drugs using a transparent pricing model.

27 Aug 2009

FDA advisory panel recommends ban of pain medications Vicodin and Percocet

An advisory panel for the Food and Drug Administration (FDA) recently recommended limiting sales of acetaminophen products like Tylenol and also recommended banning prescription pain medications Vicodin and Percocet. This recommendation will prompt more people to change their habits and focus on joint pain remedy and pain relievers found in the natural vitamin supplements industry for arthritis treatment.

27 Aug 2009

New over-the-counter eye drop provides relief to seven symptoms of eye irritation

New entries in the eye care category are changing the way people can take care of their eyes.

26 Aug 2009

Endo Pharmaceuticals gets exclusive rights to commercialize ProStrakan's FORTESTA in the U.S.

Endo Pharmaceuticals (Nasdaq: ENDP) today announced that it has signed an agreement with U.K.-based ProStrakan Group plc (LSE: PSK) for the exclusive right to commercialize FORTESTA(TM) (testosterone gel) 2 percent in the United States.

26 Aug 2009

UT Southwestern awarded $763,000 as grant to expand studies of Peregrine's anti-PS antibodies

Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that the U.S. National Institute of Allergy and Infectious Diseases (NIAID) has awarded a two-year, $763,000 grant to Philip Thorpe, Ph.D., of the University of Texas Southwestern Medical Center for research expanding its studies of anti-phosphatidylserine (anti-PS) antibodies as potential treatments for viral hemorrhagic fever (VHF) infections.

26 Aug 2009

Endo Pharmaceuticals Solutions announces the beginning of cash tender offer

Endo Pharmaceuticals announced today the commencement of a cash tender offer by its wholly-owned subsidiary, Endo Pharmaceuticals Solutions Inc., for any and all outstanding Ledgemont PhaRMA(SM) Secured 16% Notes due 2024 (the "Notes") of Ledgemont Royalty Sub LLC, Endo Pharmaceuticals Solutions Inc.'s wholly-owned subsidiary. The purpose of the tender offer is to acquire any and all Notes to reduce the consolidated interest expense of Endo.

26 Aug 2009

USP and FEUM agrees to collaborate on the development of standards for medicines

Demonstrating a significant commitment to advancing the quality of medicines for patients on behalf of both countries, the U.S. Pharmacopeial (USP) Convention and the Permanent Commission of the Pharmacopeia of the United Mexican States (FEUM) today agreed to collaborate on the development of standards for medicines.

26 Aug 2009

DAS181 inhibits H5N1 Influenza lung virus infection of human lung tissues

NexBio, Inc. announced today the publication "DAS181 Inhibits H5N1 Influenza Lung Virus Infection of Human Lung Tissues" in the September, 2009 issue of the journal Antimicrobial Agents and Chemotherapy (AAC).

26 Aug 2009

Modest decline for hypertension drug industry over the next decade

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that despite generic erosion of many branded agents -- most notably Novartis's Diovan -- the hypertension drug market will experience only modest decline over the next decade.

26 Aug 2009

FDA to review Acorda Therapeutics’ NDA for Fampridine-SR

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that the U.S. Food and Drug Administration (FDA) has confirmed that its Peripheral and Central Nervous System Drugs Advisory Committee will review the Company’s New Drug Application (NDA) for Fampridine-SR on October 14, 2009.

26 Aug 2009

FDA accepts Labopharm's response for its novel trazodone formulation

Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced the U.S. Food and Drug Administration (FDA) has accepted Labopharm's response regarding its novel formulation of the antidepressant trazodone as complete and designated it as a Class 2 resubmission. The FDA has assigned Labopharm a new Prescription Drug User Fee Act (PDUFA) action date of February 11, 2010.

26 Aug 2009

Sabril (vigabatrin) Oral Solution receives approval from FDA

Sabril (vigabatrin) Oral Solution has been approved by the U.S. Food and Drug Administration to treat infantile spasms in children ages 1 month to 2 years. Sabril is the first drug in the United States approved to treat the disorder, characterized by a severe type of seizure that usually appears in the first year of life, typically between ages 4 months and 8 months.

26 Aug 2009

Glaxosmithkline affirms safety of Alli

GSK stands firmly behind the safety and efficacy of alli. Our primary priority is patient health, and we want people to know that there is no evidence that alli causes liver damage.

26 Aug 2009

Pharmaceutical News

Viral Genetics cautions investors and the public to rely only on its own releases and disclosures

European Medicines Agency validates Schering-Plough's MAA for nomegestrol acetate/17 beta-estradiol

Prescription Solutions launches consumer website that features updated content and drug pricing tool

XenaCare Holdings to market Cobroxin pain reliever drug in U.S.

European Medicines Agency accepts reviewal of Merck's MAA for regulatory approval of vernakalant IV

Rizer XL's male enhancement formula increases sexual desire, pleasure and performance

QRxPharma completes its pilot evaluation study investigating the efficacy of MoxDuo capsules

Walgreens collaborates with Caterpillar to provide transparent prescription drug pricing for employers

FDA advisory panel recommends ban of pain medications Vicodin and Percocet

New over-the-counter eye drop provides relief to seven symptoms of eye irritation

Endo Pharmaceuticals gets exclusive rights to commercialize ProStrakan's FORTESTA in the U.S.

UT Southwestern awarded $763,000 as grant to expand studies of Peregrine's anti-PS antibodies

Endo Pharmaceuticals Solutions announces the beginning of cash tender offer

USP and FEUM agrees to collaborate on the development of standards for medicines

DAS181 inhibits H5N1 Influenza lung virus infection of human lung tissues

Modest decline for hypertension drug industry over the next decade

FDA to review Acorda Therapeutics’ NDA for Fampridine-SR

FDA accepts Labopharm's response for its novel trazodone formulation

Sabril (vigabatrin) Oral Solution receives approval from FDA

Glaxosmithkline affirms safety of Alli

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News